FATE
Fate Therapeutics Inc
NASDAQ: FATE · HEALTHCARE · BIOTECHNOLOGY
$1.25
+0.81% today
Updated 2026-04-30
Market cap
$154.63M
P/E ratio
—
P/S ratio
23.27x
EPS (TTM)
$-1.15
Dividend yield
—
52W range
$1 – $2
Volume
1.4M
WallStSmart proprietary scores
29
out of 100
Grade: F
Strong Sell
Investment rating
2.7
Growth
F6.0
Quality
B2.5
Profitability
F6.7
Valuation
B2/9
Piotroski F-Score
Weak
-3.2
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$4.94
+295.52%
12-Month target
—
—
Intrinsic (DCF)
$10.39
Margin of safety
+88.74%
1 Strong Buy5 Buy6 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ 88.74% below intrinsic value
+ Debt/equity 0.34x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -3.19 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-24.51M
- Revenue declining -26.40% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $96.30M | $63.53M | $13.63M | $6.65M | $6.65M |
| Net income | $-255.06M | $-160.93M | $-186.26M | $-136.31M | $-32.37M |
| EPS | — | — | — | — | $-1.15 |
| Free cash flow | $-283.77M | $-138.42M | $-123.60M | $-112.04M | $-24.51M |
| Profit margin | -264.86% | -253.30% | -1,366.46% | -2,051.08% | — |
Peer comparison
Smart narrative
Fate Therapeutics Inc trades at $1.25. Our Smart Value Score of 29/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -3.19, it sits in the distress. TTM revenue stands at $6.65M. Our DCF model estimates intrinsic value at $10.39.
Frequently asked questions
What is Fate Therapeutics Inc's stock price?
Fate Therapeutics Inc (FATE) trades at $1.25.
Is Fate Therapeutics Inc overvalued?
Smart Value Score 29/100 (Grade F, Strong Sell). DCF value $10.39.
What is the price target of Fate Therapeutics Inc (FATE)?
The analyst target price is $4.94, representing +295.5% upside from the current price of $1.25.
What is the intrinsic value of Fate Therapeutics Inc (FATE)?
Based on our DCF model, intrinsic value is $10.39, a +88.7% margin of safety versus $1.25.
What is Fate Therapeutics Inc's revenue?
TTM revenue is $6.65M.
Piotroski F-Score?
2/9 — weak financial health.
Altman Z-Score?
-3.19 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio23.27x
ROE-51.80%
Beta2.24
50D MA$1.29
200D MA$1.18
Shares out0.12B
Float0.10B
Short ratio—
Avg volume1.4M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—